Swiss Life Asset Management Ltd Has $5.72 Million Stock Position in United Therapeutics Corporation $UTHR

Swiss Life Asset Management Ltd lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 54.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 11,733 shares of the biotechnology company’s stock after acquiring an additional 4,134 shares during the period. Swiss Life Asset Management Ltd’s holdings in United Therapeutics were worth $5,717,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. AE Wealth Management LLC increased its holdings in United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC boosted its position in shares of United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after buying an additional 2,975 shares during the last quarter. Optimize Financial Inc purchased a new position in shares of United Therapeutics during the third quarter valued at approximately $444,000. Tobam grew its holdings in United Therapeutics by 183.9% during the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after buying an additional 4,953 shares in the last quarter. Finally, Perpetual Ltd bought a new stake in United Therapeutics during the fourth quarter worth $1,059,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $586.75, for a total transaction of $4,870,025.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at $26,504,671. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $573.10, for a total transaction of $5,444,450.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $23,218,000.30. This trade represents a 19.00% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 501,913 shares of company stock worth $278,169,037. Insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $579.54 on Thursday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm has a market cap of $24.60 billion, a PE ratio of 21.39, a P/E/G ratio of 1.84 and a beta of 0.60. The stock has a fifty day moving average price of $554.96 and a 200-day moving average price of $505.54.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the firm posted $6.63 earnings per share. As a group, equities analysts anticipate that United Therapeutics Corporation will post 27.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on UTHR shares. TD Cowen raised their price objective on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. HC Wainwright boosted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Finally, Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.